In a patient with end‑stage renal disease (ESRD) and estimated glomerular filtration rate (eGFR) <15 mL/min not on dialysis who presents with an acute gout flare, is prednisolone safe and what dosing and taper regimen should be used, especially if the patient has diabetes, hypertension, or fluid‑overload risk?

Prednisolone for Acute Gout Flare in ESRD (eGFR <15 mL/min)

Prednisolone is safe and recommended at 30–35 mg daily for 3–5 days for treating acute gout flares in patients with end-stage renal disease, as both colchicine and NSAIDs should be avoided in severe renal impairment. 1

Why Prednisolone is the Preferred Choice in ESRD

In patients with eGFR <15 mL/min, your treatment options are severely limited:

• Colchicine is contraindicated in severe renal impairment (GFR <30 mL/min) because clearance is significantly reduced, leading to accumulation and serious toxicity risk 1
• NSAIDs should be avoided due to nephrotoxicity and risk of acute kidney injury 1
• Oral corticosteroids become the first-line option when colchicine and NSAIDs are contraindicated 1

Specific Dosing Regimen

Standard dose: 30–35 mg prednisolone (or equivalent) daily for 3–5 days 1

This regimen is supported by randomized controlled trials showing equivalence to NSAIDs for pain relief in acute gout flares. One trial demonstrated that prednisolone 35 mg/day for 5 days was equivalent to naproxen 500 mg twice daily, and another showed 30 mg/day for 5 days had analgesic effectiveness equivalent to indomethacin 1.

No taper is required after a short 3–5 day course for acute flare treatment 1. The guidelines do not recommend tapering after brief corticosteroid courses for gout flares.

Special Considerations for Your Patient's Comorbidities

Diabetes

• Monitor blood glucose closely during the 3–5 day course
• Expect transient hyperglycemia requiring temporary insulin dose adjustments
• The short duration (3–5 days) minimizes metabolic impact compared to longer courses

Hypertension

• Monitor blood pressure during treatment
• The brief course limits sodium retention and blood pressure effects
• Consider holding or adjusting diuretics temporarily if needed

Fluid Overload Risk

• Prednisolone causes less mineralocorticoid effect than hydrocortisone
• The 3–5 day duration minimizes fluid retention risk
• Monitor weight and volume status, especially if patient is approaching dialysis initiation
• This remains safer than NSAIDs, which would worsen renal function and fluid retention

Critical Pitfalls to Avoid

1. Do not use colchicine even at reduced doses in eGFR <15 mL/min—the risk of serious toxicity (neuromuscular, gastrointestinal) outweighs benefits 1

2. Do not extend corticosteroid duration unnecessarily—stick to 3–5 days to minimize metabolic complications

3. Do not use NSAIDs despite their effectiveness in normal renal function—they can precipitate acute-on-chronic kidney injury 1

4. Treat early—prednisolone works best when initiated at first symptoms of flare 1

Alternative Options if Corticosteroids Are Contraindicated

If the patient has contraindications to oral corticosteroids (active infection, uncontrolled diabetes with DKA risk, severe psychiatric disease):

• Intra-articular corticosteroid injection if flare is monoarticular 1
• IL-1 blockers (anakinra, canakinumab) for patients with contraindications to all conventional therapies, though current infection is a contraindication 1

Long-Term Management Note

While treating the acute flare with prednisolone, remember that this patient needs urate-lowering therapy (ULT) given their ESRD. Allopurinol can be initiated at very low doses (≤50 mg/day) even in ESRD and titrated carefully with monitoring 2, 1. The 2020 ACR guidelines strongly recommend concomitant anti-inflammatory prophylaxis when starting ULT 2, though in ESRD this would need to be low-dose prednisone (not colchicine) given the renal contraindications.